✦ LIBER ✦

LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy

✍ Scribed by Ashton, Veronica; Zhang, Qiaoyi; Zhang, Ning Jackie; Zhao, Changgeng; Ramey, Dena Rosen; Neff, David; Tershakovec, Andrew M.; Marrett, Elizabeth

Book ID: 122146424
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 290 KB
Volume: 36
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2014.03.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Attainment of ldl-cholesterol goals is s

Attainment of ldl-cholesterol goals is suboptimal with rosuvastatin monotherapy in us patients at high cardiovascular risk

✍ Marrett, E.; Zhang, Q.; Zhao, C.; Ramey, D.; Neff, D.R.; Tershakovec, A.M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Efficacy of Switching from Statin Monoth

Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C

✍ Philippe Brudi; Maurizio Averna; Michael Farnier; Luc Missault; Helena Vaverkova 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 189 KB

C-reactive protein levels in patients at

C-reactive protein levels in patients at cardiovascular risk: EURIKA study

✍ Halcox, Julian PJ; Roy, Carine; Tubach, Florence; Banegas, José R; Dallongeville 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 220 KB

AN ANALYSIS OF THE RESIDUAL RISK OF CARD

AN ANALYSIS OF THE RESIDUAL RISK OF CARDIOVASCULAR EVENTS IN PATIENTS AT LOW DENSITY LIPOPROTEIN (LDL-C) TARGET LEVELS

✍ Simko, R.; Balu, S.; Cziraky, M.; Sarawate, C. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 71 KB

PCV89 Cost-Effectiveness Analysis of Ros

PCV89 Cost-Effectiveness Analysis of Rosuvastatin Versus Generic Atorvastatin in Patients at High Cardiovascular Risk in Spain

✍ M. Brosa; V. Barrios; J.M. Lobos; A. Serrano; M. Capel; C. Alvarez 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

MS391 EFFICACY OF SWITCHING FROM STATIN

MS391 EFFICACY OF SWITCHING FROM STATIN MONOTHERAPY TO EZETIMIBE/SIMVASTATIN 10/20 mg VERSUS ROSUVASTATIN 10 mg IN HIGH-RISK PATIENTS ANALYZED BY BASELINE LDL-C

✍ Brudi, P.; Averna, M.; Farnier, M.; Missault, L.; Vaverkova, H.; Viigimaa, L.M.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 53 KB